Kenneth Clark remembers the last time new investors moved into biotech. They came in the late 1980s.
They left in the early ’90s.
The New is back again in the form of Founders Fund, Andreessen Horowitz, Google Ventures and others who are making big bets into the life sciences.
Clark, a partner at Wilson Sonsini Goodrich & Rosati who also sat on the board of Pharmacyclics, thinks the new investors are here to stay this time. He’s driven by an increasingly popular belief that new therapies, a maturing biotech sector and new capital will combine to bring returns those new (and traditional) investors need to stay active.
